KISUNLA
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $2.1M | 7,454 | 3,178 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 773 | 69.1% |
| Consulting Fee | $400,028 | 120 | 18.9% |
| Food and Beverage | $208,043 | 6,162 | 9.8% |
| Travel and Lodging | $43,929 | 384 | 2.1% |
| Education | $1,850 | 2 | 0.1% |
| Unspecified | $262.36 | 13 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | Eli Lilly and Company | $140.87 | 6 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $120.12 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $1.37 | 0 |
Top Doctors Receiving Payments for KISUNLA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , MD | Neurology | Bolivar, MO | $82,044 | 74 |
| , MD | Neurology | Hattiesburg, MS | $80,432 | 73 |
| , M.D | Neurology | Houston, TX | $76,139 | 65 |
| , MD, PHD | Neurology | Amherst, NY | $65,316 | 50 |
| , D.O | Neurology | Pensacola, FL | $63,016 | 50 |
| , MD | Neurology | Boston, MA | $50,609 | 58 |
| , MD | Neurology | San Francisco, CA | $49,528 | 39 |
| , MD,PHD | Neurology | Washington, DC | $48,668 | 52 |
| , MD, MBA, MSC | Internal Medicine | New York, NY | $47,997 | 38 |
| , MD | Neurological Surgery | Orlando, FL | $46,494 | 36 |
| , M.D | Neurology | Stamford, CT | $45,798 | 27 |
| , M.D | Neurology | Denver, CO | $39,077 | 45 |
| , M.D | Neurology | Tampa, FL | $36,288 | 37 |
| , M.D | Neurology | Scottsdale, AZ | $33,747 | 31 |
| , M.D | Neurology | Jacksonville, FL | $33,033 | 21 |
| , M.D | Neurology | Elk Grove Village, IL | $32,437 | 28 |
| , MD | Neurology | Columbus, OH | $27,058 | 34 |
| , M.D | Behavioral Neurology & Neuropsychiatry | Willow Grove, PA | $25,943 | 25 |
| , M.D | Geriatric Psychiatry | Phoenix, AZ | $25,059 | 18 |
| , M.D | Behavioral Neurology & Neuropsychiatry | North Little Rock, AR | $24,335 | 24 |
| , DO | Neurology | Owosso, MI | $23,456 | 25 |
| , M.D | Specialist | Huntsville, AL | $22,932 | 14 |
| , M.D | Behavioral Neurology & Neuropsychiatry | San Antonio, TX | $22,798 | 18 |
| , DO | Neurology | Canton, OH | $21,307 | 24 |
| , MD | Family Medicine | Des Moines, IA | $20,852 | 26 |
Manufacturing Companies
- Lilly USA, LLC $1.9M
- Eli Lilly and Company $172,078
- Eli Lilly Export S.A. Puerto Rico Branch $135.75
Product Information
- Type Drug
- Total Payments $2.1M
- Total Doctors 3,178
- Transactions 7,454
About KISUNLA
KISUNLA is a drug associated with $2.1M in payments to 3,178 healthcare providers, recorded across 7,454 transactions in the CMS Open Payments database. The primary manufacturer is Lilly USA, LLC.
Payment data is available from 2024 to 2024. In 2024, $2.1M was paid across 7,454 transactions to 3,178 doctors.
The most common payment nature for KISUNLA is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.5M, 69.1% of total).
KISUNLA is associated with 3 research studies, including "A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6)" ($140.87).